Close

Amgen (AMGN) Granted FDA Approval for BLINCYTO (blinatumomab)

July 12, 2017 5:37 AM EDT Send to a Friend
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login